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Background: Chemokine (C-X3-C motif) receptor 1 (CX3CR1) was identified as the most differentially expressed
gene between survivors and non-survivors in two independent cohorts of septic shock patients and was proposed
as a marker of sepsis-induced immunosuppression. Whether such a biomarker is associated with mortality in the
heterogeneous group of critically ill patients is unknown. The primary objective of this study was to evaluate the
association between CX3CR1 messenger RNA (mRNA) expression and mortality in intensive care unit (ICU) patients.
The secondary objective was to evaluate similar endpoints in the subgroup of septic shock patients.
Methods: We performed a prospective, multicentre, non-interventional study in six ICUs of university hospitals in
Lyon, France. Every consecutive adult patient with systemic inflammatory response syndrome and an expected
length of stay in the ICU over 2 days was included. Whole-blood CX3CR1 mRNA expression was measured by
quantitative real-time polymerase chain reaction at day 1 (D1) and D3 after inclusion.
Results: In ICU patients (n = 725), decreased CX3CR1 mRNA expression at D1 was associated with high D7 mortality
(AUC 0.70, adjusted OR [aOR] 2.03, 95 % CI 1.19–3.46), while decreased expression at D3 was associated with increased
D28 mortality (AUC 0.64, aOR 2.34, 95 % CI 1.45–3.77). In septic shock patients (n = 279), similar associations were
observed between decreased D1 CX3CR1 mRNA expression and D7 mortality (AUC 0.69, aOR 2.76, 95 % CI 1.32–5.75)
as well as decreased D3 expression and D28 mortality (AUC 0.72, aOR 3.98, 95 % CI 1.72–9.23). These associations were
independent of lactacidaemia, Simplified Acute Physiology Score II, Sepsis-related Organ Failure Assessment score and
Charlson comorbidity index.
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Conclusions: This study represents the largest evaluation of such an mRNA marker in a heterogeneous cohort of
severely injured patients. Our results show that decreased CX3CR1 mRNA expression is associated with increased
mortality in ICU patients. This suggests a link between injury-induced immunosuppression and mortality in critically ill
patients. In this context, the monitoring of such a host response molecular biomarker could prove very helpful for the
identification of patients at high risk of death in the ICU.
Keywords: CX3CR1 mRNA, Transcriptomics, Biomarker, Mortality, Intensive care unit, Prognosis, ImmunosuppressionBackground
Intensive care units (ICUs) treat a heterogeneous group of
patients with life-threatening injuries requiring close mon-
itoring and support with high-technology medical equip-
ment and multiple medications. In this context, the search
for prognostic biomarkers that would help clinicians pre-
dict patients’ outcomes has been ongoing for years [1].
Several aspects of risk stratification biomarkers could
be of interest in the ICU, especially in the context of fi-
nancial constraints faced by the health care system and
the strong need for optimization of limited medical re-
sources. Indeed, besides use as benchmarking tools and
in inter-ICU comparative studies, accurate outcome pre-
diction based on biomarkers could be extremely useful
for improving clinical decision-making. For example,
biomarkers could help clinicians to dispense relevant
treatments to patients who might benefit from them [2].
Transcriptomics has recently emerged as a novel tool
to identify such biomarkers [3–8]. Most important, the
availability of fully automated and user-friendly molecu-
lar platforms offers concrete solutions for routine clin-
ical applications, even in ICU and emergency settings.
We previously identified chemokine (C-X3-C motif )
receptor 1 (CX3CR1) as the most differentially expressed
gene between survivors and non-survivors after septic
shock [9, 10]. CX3CR1 is the sole receptor for fractalk-
ine (CX3CL1) expressed on leucocyte subpopulations.
Interestingly, we observed an association between de-
creased CX3CR1 expression on monocytes after septic
shock and decreased functional responses of monocytes
ex vivo [10]. This provides a link between decreased
CX3CR1 and immune dysfunction after sepsis and sug-
gests that the measure of such a host response messen-
ger RNA (mRNA) marker may be useful in evaluation of
injury-induced immune alterations. However, whether
such a biomarker could be useful in the heterogeneous
group of ICU patients is unknown. Therefore, we con-
ducted a prospective, multicentre, non-interventional
study with the primary objective of studying the associ-
ation between CX3CR1 mRNA expression and risk of
death in a large cohort of critically ill patients. The sec-
ondary objective was to evaluate the association between
CX3CR1 mRNA expression and risk of death in the sub-
group of septic shock patients.Methods
Experimental design
This prospective, multicentre, non-interventional study
was conducted in six ICUs in Lyon, France. It was ap-
proved by our institutional ethical review board (Comité
d’Ethique des Centres d’investigation Clinique de l’Inter-
Région Rhône-Alpes Auvergne – IRB 5044).
Follow-up and outcomes
The primary outcome was the association of day 1 (D1)
and D3 CX3CR1 mRNA expression and risk of death
during the hospital stay of ICU patients with systemic
inflammatory response syndrome (SIRS). The secondary
outcome was the association of D1 and D3 CX3CR1
mRNA expression and risk of death during the hospital
stay in the subgroup of septic shock patients. In both
cases, mortality was evaluated at 7 days (D7) and at
28 days (D28).
Since half of the deaths in our cohort occurred before
D7 and the median ICU stay was 7 days, this time point
(i.e., D7) was used to define early mortality among the
725 patients eligible at D1. Conversely, D28 was used to
define late mortality after ICU admission among the 515
patients eligible at D3.
Patients
From December 2009 to June 2011, every consecutive
patient aged ≥18 years with an expected length of stay in
the ICU of more than 2 days was prospectively enrolled
if the patient met the criteria for SIRS as described in
the American College of Chest Physicians/Society of
Critical Care Medicine (ACCP/SCCM) 1992 consensus
statement [11] and if non-opposition to inclusion in the
protocol was obtained.
Exclusion criteria comprised immunosuppression as
defined by immunosuppressive treatment or corticoid
treatment with dosage >10 mg/day or cumulative dose
>700 mg equivalent prednisolone, aplasia as defined by
number of circulating neutrophils <500 cells/mm3, pri-
mary innate immune deficiency, and extracorporeal cir-
culation during the month before ICU admission.
No informed consent was needed, as this study was
non-interventional and complementary blood samples
in PAXgene® tubes (PreAnalytiX, Hombrechtikon,
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blood sampling after completion of routine follow-up
tests. Nevertheless, non-opposition to inclusion in the
protocol was recorded from every patient or the pa-
tient’s next of kin.
Definitions
SIRS was defined as the presence of at least two of the
following clinical criteria: temperature >38 °C or <36 °C,
heart rate >90 beats/minute, respiratory rate >20 breaths
per minute or PaCO2 < 32 mmHg (4.3 kPa), and leuco-
cyte count >12,000/mm3 or <4000/mm3 [11].
Sepsis was defined as the presence of a proven (visible
either clinically/surgically, radiologically or microbio-
logically) infection or a highly suspected infection at in-
clusion. Following the definitions proposed by Vincent
et al., which partly rule out the former definitions of sep-
sis and severe sepsis described in the ACCP/SCCM
1992 consensus conference statement, sepsis was sim-
ply defined as an infection requiring ICU admission
[12].
Shock was defined as persistent hypotension des-
pite adequate fluid resuscitation requiring the use of
epinephrine or norepinephrine at a dose >0.25 μg/kg/
minute [13].
Antibiotic treatment was considered to be appropriate
if all the pathogenic microorganisms were sensitive to at
least one of the administered antimicrobial drugs as de-
termined by an in vitro sensitivity pattern. In cases of
culture-negative infection, treatment was considered ap-
propriate if consistent with the local anti-infectious
protocols.
Data collection at inclusion
The following demographic, clinical and biochemical
data were collected at patient admission and/or inclu-
sion in the protocol:
1. Demographic characteristics: age and sex
2. Clinical scores: Simplified Acute Physiology Score II
(SAPS II) (range 0–163 [14], calculated at inclusion),
Sepsis-related Organ Failure Assessment (SOFA)
score (range 0–24 [15], calculated at inclusion and
at D3) and Charlson comorbidity index (range 0–32
[16] for which age was not taken into account).
3. Lactic acid concentration (at D1 and at D3)
4. Need for respiratory (mechanical ventilation),
haemodynamic (vasopressor treatment) or renal
(renal replacement therapy) support
5. Presence of shock (defined as a cardiovascular SOFA
score of 4)
6. Diagnostic category (planned or urgent, surgery or
medical)
7. Presence of trauma8. Presence of sepsis (either community- or hospital-
acquired)
9. Characteristics of infection if relevant (site, type of
detection, identified germs)
10.Presence of an anti-infectious treatment if relevant
and its adequacy either to the antibiogram or to the
local anti-infectious protocol
RNA extraction, reverse transcription and quantitative
polymerase chain reaction
PAXgene® tubes were collected from patients within the
first 12 h after inclusion in the protocol (D1) and at D3.
Total RNA was extracted using the PAXgene® Blood
RNA Kit (PreAnalytiX). Before RNA elution, the residual
genomic DNA was digested using the RNase-Free
DNase Set (QIAGEN, Hilden, Germany). Total RNA
was reverse-transcribed into complementary DNA
(cDNA) using the SuperScript VILO cDNA Synthesis
Kit (Life Technologies, Carlsbad, CA, USA). The candi-
date gene was quantified using quantitative real-time
polymerase chain reactions. Polymerase chain reactions
(PCRs) were performed in a LightCycler instrument
(Roche Diagnostics, Risch-Rotkreuz, Switzerland) using
the standard TaqMan Fast Advanced Master Mix PCR
kit according to the manufacturer’s instructions (Applied
Biosystems, Foster City, CA, USA). Thermocycling was
performed in a final volume of 20 μl containing 5 μM of
required primers and 1 μM of required probe. PCR was
performed with an initial denaturation step of 10 minutes
at 95 °C, followed by 45 cycles of a touch-down PCR
protocol (10 seconds at 95 °C, 29 seconds of annealing
at 68 °C and a 1-second extension at 72 °C). The cDNA
standards were prepared from purified PCR amplicons
obtained with the corresponding primers (Additional
file 1: Table S1). The second derivative maximum
method was used with the LightCycler software to
automatically determine the crossing point for individ-
ual samples, as previously described. Standard curves were
generated by using quadruplicate cDNA standard. Relative
standard curves describing the PCR efficiency of selected
genes were created and used to perform efficiency-
corrected quantification with the LightCycler Relative
Quantification software (Roche Diagnostics). Gene expres-
sion normalization was performed using a selected house-
keeping gene (hypoxanthine phosphoribosyltransferase 1
[HPRT1]), and results were expressed as calibrated nor-
malized relative quantity (CNRQ) [17]. CX3CR1 expres-
sion and CX3CR1 CNRQ are equivalent terms.
Statistical analysis
The descriptive analyses comparing surviving and non-
surviving patients at D7 and D28 (all-cause mortality)
after ICU admission were completed with the usual ap-
propriate tests, such as the t test or Mann-Whitney U
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qualitative variables. The Monte Carlo resampling
method was used to estimate the p value of the χ2 test of
independence in cases of an expected frequency <5. ICU
survival curves were created using the Kaplan-Meier
method. Every patient was followed for 28 days in the
ICU and after ICU discharge. The results of the log-rank
tests were associated with the survival representations.
ROC curves were built for CX3CR1 expression levels at
D1 and D3 according to D7 and D28 mortality, respect-
ively. Best cut-off values (i.e., maximized sensitivity and
specificity) for CX3CR1 mRNA expression prediction of
mortality were identified according to the calculation of
Youden indexes derived from ROC curve analyses. Uni-
variate and multivariate analyses of mortality outcomes
at D7 and D28 were studied with logistic regression. Pa-
rameters with a p value <0.1 in univariate analyses were
kept in multivariate analyses. Parameters with >20 %
missing values were not included in multivariate ana-
lyses. The 0.632+ bootstrap method was applied to
adjust for potential overestimation of diagnostic per-
formance and to estimate internal validity. For each
model, 1000 resamplings with replacement were per-
formed. The 95 % CI represents the 2.5th and 97.5th
percentiles of estimates obtained in bootstrap resamples.
All bootstrap estimations were performed using the
ModelGood package in R. The level of significance was
set at 5 %, and the results were described with a 95 % CI.
The analyses were performed with IBM SPSS Statistics
version 20 software (IBM, Armonk, NY, USA).
Results
Cohort description
Between December 2009 and June 2011, 852 ICU pa-
tients were screened for eligibility. After exclusion due
to ICU discharge within the first 48 h, 749 patients were
included. Because of technical issues, samples from 24
of these patients could not be processed at D1. There-
fore, 725 patients were ultimately analysed (Fig. 1). Their
clinical characteristics are described in Table 1. At D3,
515 patients were still alive and had samples available
for analysis. The clinical characteristics of this subcohort
of patients at admission were not different from those of
the overall cohort.
In the total cohort (n = 749), 220 patients died within
28 days (D28 mortality 29 %) (Additional file 2: Figure S1).
Half of these deaths occurred before D7 (D7 mortality
15 %) and one-third occurred before D3 (D3 mortality
10 %). The median ICU stay was 7 days.
In the D1–D7 period (n = 725), non-survivors were
significantly older (p < 0.001) and presented with signifi-
cantly higher SAPS II (p < 0.001) and SOFA (p < 0.001)
scores and increased lactacidaemia at D1 (p < 0.001).
Non-survivors were more frequently in shock at ICUadmission (p < 0.001) but had infections less frequently
than survivors (p = 0.023).
In the D3–D28 period in the subgroup of patients
alive at D3 (n = 515), D28 mortality was 23 % (n = 117
non-survivors). Non-survivors were significantly older
(p < 0.001) and had higher SAPS II (p < 0.001) and SOFA
(p < 0.001) scores and increased lactacidaemia at D3
(p < 0.001).
Primary endpoint
At D1, CX3CR1 mRNA expression was significantly
lower in non-survivors than in D7 survivors (p < 0.0001)
(Fig. 2a).
On the basis of ROC curve analysis, a threshold of
0.085 was defined as the best cut-off value for the pre-
diction of D7 mortality (AUC 0.70, 95 % CI 0.65–0.76,
sensitivity [Se] 55 %, specificity [Sp] 77 %, positive pre-
dictive value [PPV] 30 %, negative predictive value
[NPV] 91 %, positive likelihood ratio [LR+] 2.42, nega-
tive likelihood ratio [LR−] 0.58). The internal validity of
these results was confirmed using a bootstrapping tech-
nique (AUC 0.70, 95 % CI 0.63–0.77). Using this thresh-
old, Kaplan-Meier survival curves were established
(Fig. 2b). Log-rank test analysis showed that patients
with D1 CX3CR1 mRNA expression over the threshold
had better survival than patients with CX3CR1 expres-
sion below the cut-off (91 % and 70 %, respectively;
p < 0.001).
In univariate and multivariate logistic regression ana-
lyses, low CX3CR1 expression (below threshold of
0.085) remained significantly associated with D7 mortal-
ity independently of confounding parameters (adjusted
OR [aOR] 2.03, 95 % CI 1.19–3.46, p = 0.009) (Table 2).
In these models, SAPS II and SOFA scores, presence of
sepsis and lactacidaemia at D1 were also associated with
D7 mortality. Of note, because the SOFA score was
based on norepinephrine or epinephrine administration,
a similar multivariate analysis including the presence of
shock instead of the SOFA score was performed. In this
analysis, neither shock nor Charlson comorbidity index
was associated with D7 mortality (Additional file 3:
Table S2A).
At D3, CX3CR1 mRNA expression was lower in pa-
tients who died within 28 days after admission (n = 117)
versus survivors (n = 398) (p < 0.0001) (Fig. 2c). Based on
ROC curve analysis, the best cut-off value for D3
CX3CR1 mRNA expression association with D28 mor-
tality was 0.246 (AUC 0.64, 95 % CI 0.58–0.71, Se 73 %,
Sp 56 %, PPV 85 %, NPV 38 %, LR+ 1.65, LR− 0.48).
Again, the internal validity of these results was con-
firmed using a bootstrapping technique (AUC 0.64,
95 % CI 0.56–0.72). Kaplan-Meier survival curves
were generated with this threshold. Log-rank test ana-
lysis showed that D28 survival was significantly higher
Fig. 1 Study flowchart. Between December 2009 and June 2011, a total of 852 critically ill patients were screened for eligibility. After exclusion for
technical reasons or intensive care unit discharge within the first 48 h, 725 patients were ultimately included in the study. D day
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over threshold than in patients with CX3CR1 expres-
sion below the cut-off value (85 % versus 62 %, re-
spectively; p < 0.001) (Fig. 2d). Finally, in multivariate
analysis, low CX3CR1 expression at D3 was associ-
ated with increased risk of death at D28, with an
aOR of 2.34 (95 % CI 1.45–3.77; p < 0.001) (Table 2B).
This association was independent of SAPS II and
SOFA scores as well as the Charlson comorbidity
index. Of note, due to the high number of missing
values for lactacidaemia at D3, this parameter was
not included in the multivariate analysis. In multivari-
ate analysis, replacement of SOFA score at D3 by
presence of shock at D3 did not reveal any significant
association between this last parameter and D28 mor-
tality (Additional file 3: Table S2B).
Secondary endpoint: specificity of septic shock patients
The clinical characteristics of septic shock patients are
presented in Table 3.At D1, CX3CR1 mRNA expression was lower in septic
shock patients who died within the first week after ICU
admission than in D7 survivors (p < 0.0001) (Fig. 3a).
On the basis of ROC curve analysis, a threshold of
0.073 was defined as the best cut-off value for the
prediction of D7 mortality (AUC 0.67, 95 % CI 0.59–
0.76, Se 63 %, Sp 68 %, PPV 33 %, NPV 88 %, LR+
1.94, LR− 0.55). Again, the internal validity of these
results was confirmed using a bootstrapping tech-
nique (AUC 0.67, 95 % CI 0.59–0.76). Using this
threshold, Kaplan-Meier survival curves were estab-
lished (Fig. 3b). Log-rank test analysis showed that
patients with CX3CR1 mRNA expression at D1 over
the threshold had a better survival than patients with
CX3CR1 expression below the cut-off value (88 %
and 65 %, respectively; p < 0.001).
In univariate and multivariate logistic regression ana-
lyses, low CX3CR1 expression (below threshold of
0.073) remained associated with D7 mortality independ-
ently of confounding parameters (aOR 2.76, 95 % CI
Table 1 Clinical and demographic characteristics of critically ill patients in the study













Age, years 65 [54–76] 64 [52–75] 71 [62–79]a 64 [53–75] 62 [51–74] 73 [63–80]a
Male sex 450 (62.1 %) 391 (63.5 %) 59 (54.1 %) 335 (65.0 %) 252 (63.3 %) 83 (70.9 %)
SAPS II 56 [42–69] 53 [40–65] 79 [65–97]a 55 [42–67] 52 [39–63] 62 [51–73]a
SOFA score at D1 9 [6–12] 8 [6–11] 13 [10–15]a 6 [4–10] 6 [3–8] 9 [6–13]a
Charlson comorbidity index score 2 [0–3] 2 [0–3] 2 [1–4] 1 [0–3] 1 [0–3] 2 [1–4]a
Lactic acid, mmol/L 2.2 [1.4–3.6] 2.0 [1.3–3.1] 4.2 [2.5–8.9]a 1.4 [1.1–2.0] 1.3 [1.1–1.8] 1.8 [1.4–2.5]a
Respiratory supportb 581 (80.1 %) 478 (77.6 %) 103 (94.5 %)a 402 (78.1 %) 295 (74.1 %) 107 (91.5 %)a
Haemodynamic supportc 489 (67.4 %) 397 (64.4 %) 92 (84.4 %)a 231 (44.9 %) 162 (40.7 %) 69 (59.0 %)a
Shock at D1d 375 (51.7 %) 288 (46.8) 87 (79.8 %)a 257 (49.9 %) 193 (48.5 %) 64 (54.7 %)
Shock at D3d 121 (23.5 %) 76 (19.1 %) 45 (38.5 %)a
Septic shock 279 (38.5 %) 222 (36.0 %) 57 (52.3 %)e 192 (37.3 %) 146 (36.7 %) 46 (39.3 %)
Diagnostic category
Medical 502 (69.2 %) 421 (68.4 %) 81 (74.3 %) 357 (69.3 %) 270 (67.8 %) 87 (74.4 %)
Planned surgery 32 (4.4 %) 31 (5.0 %) 1 (0.9 %) 24 (4.7 %) 18 (4.5 %) 6 (5.1 %)
Urgent surgery 191 (26.4 %) 164 (26.6 %) 27 (24.8 %) 134 (26.0 %) 110 (27.6 %) 24 (20.5 %)
Trauma 67 (9.2 %) 63 (10.2 %) 4 (3.7 %) 57 (11.1 %) 54 (13.6 %) 3 (2.6 %)e
Sepsis 506 (69.8 %) 440 (71.4 %) 66 (60.6 %) 364 (70.7 %) 280 (70.3 %) 84 (71.8 %)
Community-acquired 323 (44.6 %) 283 (45.9 %) 40 (36.7 %) 229 (44.5 %) 183 (46.0 %) 46 (39.3 %)
Hospital-acquired 183 (25.2 %) 157 (25.5 %) 26 (23.9 %) 135 (26.2 %)e 97 (24.4 %) 38 (32.5 %)
Site of infection
Respiratory 260 (35.9 %) 229 (37.2 %) 31 (28.4 %) 197 (38.3 %) 149 (37.4 %) 48 (41.0 %)
Abdominal 113 (15.6 %) 90 (14.6 %) 23 (21.1 %) 74 (14.4 %) 50 (12.6 %) 24 (20.5 %)
Others 133 (18.3 %) 121 (19.6 %) 12 (11.0 %) 93 (18.1 %) 81 (20.4 %) 12 (10.3 %)
Type of detection
Clinical + imaging 124 (24.5 %) 108 (24.5 %) 16 (24.2 %) 96 (18.6 %) 73 (18.3 %) 23 (19.7 %)
Clinical + surgery 23 (4.5 %) 17 (3.9 %) 6 (9.1 %) 14 (2.7 %) 10 (2.5 %) 4 (3.4 %)
Microbiology 339 (67.0 %) 297 (67.5 %) 42 (63.6 %) 240 (46.6 %) 186 (46.7 %) 54 (46.2 %)
Suspected 20 (4.0 %) 18 (4.0 %) 2 (3.1 %) 14 (2.7 %) 11 (2.8 %) 3 (2.6 %)
Identified germ categories
Gram-negative 196 (57.8 %) 172 (57.9 %) 24 (57.1 %) 134 (55.8 %) 107 (57.5 %) 27 (50.0 %)
Gram-positive 183 (54.0 %) 162 (54.5 %) 21 (50.0 %) 140 (45.6 %) 105 (56.5 %) 35 (64.8 %)
Fungi 8 (2.4 %) 8 (2.7 %) 0 (0.0 %) 6 (2.8 %) 3 (1.8 %) 3 (6.4 %)
Plurimicrobial 124 (36.6 %) 112 (37.7 %) 12 (28.6 %) 95 (39.6 %) 74 (39.8 %) 21 (38.9 %)
Anti-infectious treatment
Adequacy 487 (96.4 %) 429 (97.5 %) 58 (89.2 %) 356 (97.8 %) 274 (97.9 %) 82 (97.6 %)
To the antibiogram 291 (59.8 %) 258 (60.1 %) 33 (56.9 %) 211 (59.3 %) 163 (59.5 %) 48 (58.5 %)
To the protocol 196 (40.3 %) 171 (39.9 %) 25 (43.1 %) 145 (40.7 %) 111 (40.5 %) 34 (41.5 %)
D day, SAPS II Simplified Acute Physiology Score II, SOFA Sepsis-related Organ Failure Assessment
Results are presented as number and percent or median and interquartile range. Comparisons between survivors and non-survivors were completed with the




dTreatment with norepinephrine ≥0.25 μg/kg/minute or epinephrine
ep < 0.01
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Fig. 2 Association between chemokine (C-X3-C motif) receptor 1 (CX3CR1) messenger RNA (mRNA) levels at day 1 (D1) or day 3 and early (day 7)
or late (day 28) mortality in critically ill patients. CX3CR1 mRNA levels were measured by quantitative real-time polymerase chain reaction in
whole-blood samples of a cohort of 725 adult intensive care unit (ICU) patients. The Mann-Whitney U test was used to compare CX3CR1 mRNA
levels in survivors versus non-survivors. Kaplan-Meier survival curves were established after stratification based on thresholds defined in ROC curve
analyses. A p value <0.05 was considered statistically significant. a CX3CR1 mRNA levels at D1 in ICU patients were significantly different between
D7 survivors and non-survivors. b Log-rank test showed that patients with D1 CX3CR1 mRNA levels above the threshold had a significantly better
survival than patients with CX3CR1 mRNA levels below the threshold. c CX3CR1 mRNA levels at D3 in ICU patients were significantly different
between D28 survivors and non-survivors. d Log-rank test showed that patients with D3 CX3CR1 mRNA levels above the threshold had a significantly
better survival than patients with CX3CR1 mRNA levels below the threshold
Friggeri et al. Critical Care  (2016) 20:204 Page 7 of 131.32–5.75) (Table 4). In this model, SAPS II was also as-
sociated with D7 mortality, whereas the Charlson co-
morbidity index score and lactacidaemia did not show
any significant association.
At D3, 192 septic shock patients were still alive.
CX3CR1 mRNA expression was significantly lower in
patients who died before D28 than in survivors (Fig. 3c).
Based on ROC curve analysis, the best cut-off value for
D3 CX3CR1 mRNA association with D28 mortality was
0.253 (AUC 0.72, 95 % CI 0.61–0.81, Se 59 %, Sp 83 %,
PPV 92 %, NPV 38 %, LR+ 3.38, LR− 0.50). Again, the
internal validity of these results was confirmed using a
bootstrapping technique (AUC 0.71, 95 % CI 0.58–0.84).
Kaplan-Meier survival curves were generated with this
threshold. Log-rank test analysis showed that 28-day
survival was higher in the group of septic shock patients
with D3 CX3CR1 expression over the threshold than in
patients with CX3CR1 expression below the cut-offvalue (89 % versus 60 %, respectively; p < 0.001) (Fig. 3d).
In univariate and multivariate analyses, low CX3CR1 ex-
pression at D3 was associated with increased risk of
death at D28, with an aOR of 3.98 (95 % CI 1.72–
9.23; p = 0.001) (Table 4). This was independent of
SAPS II and SOFA scores as well as the Charlson co-
morbidity index score.
Discussion
We demonstrate, for the first time to our knowledge,
that decreased CX3CR1 mRNA expression is associated
with early and late mortality in critically ill patients inde-
pendently of initial severity, organ dysfunction, existing
comorbidities and metabolic distress. This represents
the largest study of such transcriptomic markers’ associ-
ation with mortality in ICU patients. In addition, this
study validates, in a large cohort of patients, our previ-
ous results showing that decreased CX3CR1 mRNA is
Table 2 Univariate and multivariate analyses of mortality according to CX3CR1 messenger RNA expression in critically ill patients
Univariate analysis Multivariate analysis
Variable OR (95 % CI) p Value OR (95 % CI) p Value
D7 mortality and CX3CR1 mRNA expression at D1
CX3CR1 at D1 < 0.085 4.01 (2.63–6.11) <0.001 2.03 (1.19–3.46) 0.009
SAPS II 1.08 (1.06–1.09) <0.001 1.06 (1.04–1.08) <0.001
Sepsis 0.61 (0.40–0.94) 0.023 0.37 (0.22–0.65) <0.001
SOFA score at D1 1.35 (1.27–1.44) <0.001 1.09 (1.01–1.19) 0.047
Lactate at D1a 1.27 (1.19–1.34) <0.001 1.11 (1.03–1.19) 0.005
Charlson comorbidity index 1.08 (0.99–1.18) 0.085 0.99 (0.88–1.10) 0.813
D28 mortality and CX3CR1 mRNA expression at D3
CX3CR1 at D3 < 0.246 3.33 (2.17–5.10) <0.001 2.34 (1.45–3.77) <0.001
Charlson comorbidity index 1.19 (1.09–1.30) <0.001 1.15 (1.05–1.27) 0.004
SAPS II 1.04 (1.03–1.05) <0.001 1.02 (1.01–1.04) 0.002
SOFA score at D3 1.20 (1.14–1.26) <0.001 1.11 (1.05–1.18) 0.001
Lactate at D3b 2.12 (1.57–2.86) <0.001
Sepsis 1.07 (0.68–1.69) 0.763
Abbreviations: D day, SAPS II Simplified Acute Physiology Score II, SOFA Sepsis-related Organ Failure Assessment, CX3CR1 chemokine (C-X3-C motif) receptor 1
Univariate and multivariate analyses on mortality were studied through logistic regressions
a33 missing values
b140 missing values
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This suggests that the monitoring of this host re-
sponse biomarker in ICU patients may provide infor-
mation complementary to the usual risk stratification
parameters.
Researchers in numerous small observational studies
have described the rapid modification of several immune
parameters after injury and the association between the
extent or duration of these alterations and increased risk
of death in these patients [18]. Therefore, in the context
of clinical trials already underway in which researchers
are evaluating immunoadjuvant therapies in sepsis [19],
host response biomarkers are being evaluated as risk
stratification parameters in ICU patients. Considering
the constantly evolving immune response after severe
injury, such biomarkers could be used as a stratification
tool or for treatment follow-up [20]. While some
markers, such as decreased human leucocyte antigen
(HLA)-DR expression on monocytes or lymphopenia,
have been proposed as immunomonitoring tools [20],
the monitoring of several different markers included in a
panel is probably required to accurately assess patients’
immune status after injury [21]. In this context, consid-
ering the recent developments of standardized molecular
biology techniques, the evaluation of transcriptomic
markers presents the advantage of now being fully auto-
mated and therefore available with very low pre-
analytical constraints [20]. This would most likely facili-
tate their use on a routine basis, as opposed to markersmonitored with less standardized techniques. However,
to date, the capacity of such mRNA marker to predict
deleterious outcomes in ICU patients has never been
evaluated in a large cohort of critically ill patients. In the
present study, we evaluated the performance of CX3CR1
mRNA level in the prediction of mortality in a cohort of
more than 720 ICU patients. This represents the largest
clinical evaluation of a molecular host response marker
in ICU patients.
CX3CR1 is a receptor expressed on leucocyte subpop-
ulations. The CX3CR1 ligand (fractalkine) is the only
member of the CX3C chemokine subfamily. CX3CR1
has a role in cell chemotaxis to sites of inflammation
through interaction with fractalkine fixed on activated
endothelial cells. In 2007, Auffray et al. showed that
CX3CR1 is overexpressed on “patroller” monocytes and
is required for their rapid tissue invasion at the infection
site [22]. Interestingly, several studies investigated the
expression of CX3CR1 after severe injuries. First, in a
microarray study, we identified this gene as the most
downregulated gene between survivors and non-
survivors of septic shock [9]. This result was confirmed
in a subsequent cohort of septic shock patients at both
the mRNA and protein levels [10]. Interestingly, de-
creased CX3CR1 expression on monocytes from septic
patients was associated with their decreased activation
after ex vivo stimulation. This provides a link between
decreased CX3CR1 and immune dysfunction after
sepsis. In further studies in murine models of sepsis,
Table 3 Clinical and demographic characteristics of septic shock patients













Age, years 67 [58–77] 67 [57–77] 69 [62–77] 67 [57–78] 67 [56–77] 73 [62–79]
Male sex 171 (61.3 %) 140 (63.1 %) 31 (54.4 %) 122 (63.5 %) 91 (62.3 %) 31 (67.4 %)
SAPS II 64 [52–78] 59 [48–71] 88 [70–98] 60 [50–73] 58 [48–70] 68 [57–80]
SOFA score at D1 11 [9–13] 10 [8–12] 14 [12–16] 8 [5–12] 8 [4–11] 12 [8–15]
Charlson comorbidity index score 2 [1–3] 2 [1–3] 2 [1–4] 2 [1–3] 2 [1–3] 3 [1–4]
Lactic acid, mmol/La 2.6 [1.8–5.2] 2.5 [1.7–3.9] 4.8 [2.7–8.8] 1.6 [1.2–2.2] 2.2 [1.6–3.4] 3.1 [1.9–6.1]
Respiratory supportb 243 (87.1 %) 187 (84.2 %) 56 (98.1 %) 157 (81.8 %) 117 (80.1 %) 40 (87.0 %)
Diagnostic category
Medical 184 (65.9 %) 144 (64.9 %) 40 (70.2 %) 127 (66.1 %) 98 (67.1 %) 29 (63.0 %)
Planned surgery 10 (3.6 %) 10 (4.5 %) 0 (0.0 %) 6 (3.1 %) 5 (3.4 %) 1 (2.2 %)
Urgent surgery 85 (30.5 %) 68 (30.6 %) 17 (29.8 %) 59 (30.7 %) 43 (29.4 %) 16 (34.8 %)
Type of sepsis acquisition
Community-acquired 169 (60.6 %) 135 (60.8 %) 34 (59.6 %) 114 (59.4 %) 92 (63.0 %) 22 (47.8 %)
Hospital-acquired 110 (39.4 %) 87 (39.2 %) 23 (40.4 %) 78 (40.6 %) 54 (37.0 %) 24 (52.2 %)
Site of infection
Respiratory 130 (46.6 %) 107 (48.2 %) 23 (40.4 %) 92 (47.9 %) 72 (49.3 %) 20 (43.5 %)
Abdominal 67 (24.0 %) 49 (22.1 %) 18 (31.6 %) 43 (22.4 %) 27 (18.5 %) 16 (34.8 %)
Others 82 (29.4 %) 66 (29.7 %) 16 (28.0 %) 57 (29.6 %) 47 (32.2 %) 10 (21.7 %)
Type of detection
Clinical + imaging 55 (19.7 %) 43 (19.4 %) 12 (21.1 %) 39 (20.3 %) 27 (18.5 %) 12 (26.1 %)
Clinical + surgery 15 (5.4 %) 9 (4.1 %) 6 (10.5 %) 8 (4.2 %) 5 (3.4 %) 3 (6.5 %)
Microbiology 198 (71 %) 160 (72.1 %) 38 (66.7 %) 136 (70.8 %) 106 (72.6 %) 30 (65.2 %)
Suspected 11 (3.9 %) 10 (4.5 %) 1 (1.8 %) 9 (4.7 %) 8 (5.5 %) 1 (2.2 %)
D day, SAPS II Simplified Acute Physiology Score II, SOFA Sepsis-related Organ Failure Assessment
Results are presented as number and percent or median and interquartile range
aLactacidaemia: 275 values at D1, 159 values at D3
bMechanical ventilation
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ial killing and host defence against infection as well as in
sepsis-induced organ dysfunction [23–26]. This all sug-
gests that measurement of such mRNA markers may
help in evaluation of injury-induced immune alterations.
Interestingly, besides sepsis, decreased CX3CR1 mRNA
expression was also described in sterile inflammation,
such as major vascular surgery [27]. Of note, in a recent
study of more than 1100 patients, Hoogendijk et al.
reported that plasma fractalkine level was positively
correlated with severity in patients with sepsis admitted
to the ICU [28]. Therefore, the tandem CX3CR1-
fractalkine may represent a good prognostic marker in
ICU patients. However, the performance of this marker
as a risk stratification tool in total ICU patients has not
been described yet. Therefore, in the present study, we
evaluated the association between CX3CR1 mRNA ex-
pression and risk of death in a large cohort of criticallyill patients. In addition, we confirmed the association be-
tween CX3CR1 mRNA expression and risk of death in
the subgroup of septic shock patients.
We chose to evaluate both early (i.e., before D7) and
late (i.e., before D28) mortality, hypothesizing that pa-
rameters associated with mortality after ICU admission
may evolve over time. Indeed, we observed that the clin-
ical parameters associated with mortality were different
when we considered early versus late deaths. This was
the case both in the total cohort of ICU patients and in
the subgroup of septic shock patients. For example, in
the multivariate analyses, Charlson comorbidity index,
illustrating patients’ comorbidities, was not associated
with early mortality but rather with late deaths. Simi-
larly, SOFA score at D1 or the presence of shock at D1
was not associated with early death, while the SOFA
score at D3 was significantly associated with D28 mor-
tality. This suggests that the later course of ICU patients
Fig. 3 Association between chemokine (C-X3-C motif) receptor 1 (CX3CR1) messenger RNA (mRNA) levels at day 1 (D1) or day 3 and early (day 7)
or late (day 28) mortality in septic shock patients. CX3CR1 mRNA level was measured by quantitative real-time polymerase chain reaction in
whole-blood samples in a cohort of 279 adult septic shock patients. The Mann-Whitney U test was used to compare CX3CR1 mRNA levels in
survivors versus non-survivors. Kaplan-Meier survival curves were established after stratification on the basis of thresholds defined in ROC curve
analyses. A p value <0.05 was considered statistically significant. a CX3CR1 mRNA levels at D1 in septic shock patients were significantly different
between D7 survivors and non-survivors. b Log-rank test showed that patients with D1 CX3CR1 mRNA levels over the threshold had a significantly
better survival than patients with CX3CR1 mRNA levels below threshold. c CX3CR1 mRNA levels at D3 in septic shock patients were significantly
different between D28 survivors and non-survivors. d Log-rank test showed that patients with D3 CX3CR1 mRNA levels over the threshold had a
significantly better survival than patients with CX3CR1 mRNA levels below the threshold. ICU intensive care unit
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medical background (such as comorbidities) and the per-
sistence of organ dysfunction. Conversely, early deaths
may be related mostly to the severity of the initial insult.
Interestingly, host immune response assessed by CX3CR1
mRNA expression constantly remained associated with
both early and late outcomes. This may illustrate that
alterations of the host immune response after severe
injury may play a role in mortality in the ICU and
therefore supports the use of immunoadjuvant therap-
ies in sepsis.
Different CX3CR1 thresholds were selected for predic-
tion of D7 versus D28 mortality. Indeed, cut-off values
for the predictive capacity of CX3CR1 at D1 were very
low compared with cut-offs at D3. This may illustrate
the evolution of the host immune response over time
after severe aggression. Severe injury strongly impacts
the host immune response by inducing a “genomicstorm” [4, 6]. However, in patients who survive this ini-
tial aggression, their immune status should return to
normal. Failure to return to normal may lead to late
mortality [18, 19]. Interestingly, these cut-off values were
very similar between ICU patients and the subcohort of
septic shock patients. This suggests that underlying
pathophysiological mechanisms associated with clinical
severity are shared by sterile inflammation and sepsis
[4, 12, 29, 30]. In our results, the association between
lower CX3CR1 expression and fatal outcome was in-
dependent of the presence of either an infection or a
shock. Interestingly, non-infectious SIRS seems to be
as deleterious as septic shock [31, 32]. In the sub-
group of non-infected patients with SIRS, we also ob-
served a significant association between decreased
CX3CR1 mRNA level at D1 and D7 mortality (AUC
0.75, 95 % CI 0.66–0.84). In univariate and multivariate lo-
gistic regression analyses, low CX3CR1 expression (below
Table 4 Univariate and multivariate analyses of mortality according to CX3CR1 messenger RNA expression in septic shock patients
Univariate analysis Multivariate analysis
Variable OR (95 % CI) p Value OR (95 % CI) p Value
D7 mortality and CX3CR1 mRNA expression at D1
Charlson comorbidity index score 1.09 (0.96–1.23) 0.205
CX3CR1 at D1 < 0.073 3.97 (2.16–7.30) <0.001 2.76 (1.32–5.75) 0.007
SAPS II 1.08 (1.06–1.11) <0.001 1.07 (1.04–1.09) <0.001
SOFA score at D1 1.41 (1.26–1.57) <0.001 1.15 (1.00–1.31) 0.690
Lactate at D1a 1.20 (1.12–1.29) <0.001 1.06 (0.96–1.16) 0.235
D28 mortality and CX3CR1 mRNA expression at D3
Charlson comorbidity index score 1.15 (1.00–1.33) 0.050 1.16 (0.99–1.36) 0.072
CX3CR1 at D3 < 0.253 5.58 (2.62–11.9) <0.001 3.98 (1.72–9.23) 0.001
SAPS II 1.03 (1.01–1.05) 0.005 1.02 (0.99–1.04) 0.198
SOFA score at D3 1.20 (1.11–1.30) <0.001 1.11 (1.01–1.22) 0.031
D day, SAPS II Simplified Acute Physiology Score II, SOFA Sepsis-related Organ Failure Assessment, CX3CR1 chemokine (C-X3-C motif) receptor 1
Univariate and multivariate analyses of mortality were studied using logistic regression
aFour missing values
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significantly associated with D7 mortality independently
of confounding parameters (aOR 3.63, 95 % CI 1.43–9.20,
p = 0.007). However, in this group of patients, no associ-
ation between D3 CX3CR1 mRNA level and D28 mortal-
ity was observed.
This study has some limitations. In particular, we did
not include measurement of other markers of injury-
induced immunosuppression, such as monocytic HLA-
DR. Therefore, we could not compare the performance
of our transcriptomic marker versus such a “gold stand-
ard” parameter in the present cohort. In addition, as no
specific immune function tests were performed, we can-
not definitively prove that decreased CX3CR1 mRNA is
associated with immune dysfunction in ICU patients.
However, considering the interesting results obtained,
these two aspects need to be confirmed in a dedicated
clinical study.
Conclusions
We observed that decreased CX3CR1 mRNA expres-
sion is a very early phenomenon in critically ill pa-
tients and is associated with mortality independently
of the presence of shock or sepsis. The recent pro-
gress in molecular biology techniques and the devel-
opment of standardized, fully automated molecular
biology platforms should ensure the availability of
measurement of this marker around the clock for
monitoring of host response in ICU patients. We sug-
gest that the measurement of this marker should be
included in a panel of host response markers in
forthcoming clinical trials in severely injured patients
to identify the group of patients with a high risk of
death after initial injury.Additional files
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